Cyclopropanes with central nervous system activity
View Patent ↗Disclosed are aromatic cyclopropane compounds with CNS activity. These compounds can be used for alleviating symptoms of CNS disorders.
1. A compound having the following structure:
or its enantiomer, wherein R1 is an alkane of 3 carbons or less, R2 consists of one or more substituents selected from the group consisting of hydrogen, halogen, alkane of 3 carbons or less, and adjacent ring forming a naphthyl group, and R3 consists of one or more substituents selected from the group consisting of hydrogen, halogen, alkane of 3 carbons or less, and adjacent ring forming a naphthyl group.
2. A compound as in claim 1 wherein R1 is a methyl group, and wherein, optionally, the amino nitrogen is present as a hydrochloric acid salt.
3. A compound as in claim 2 wherein either R2 or R3 consist of hydrogen substituents.
4. A compound as in claim 2 wherein either R2 or R3 consist of p- and m-chlorine substituents.
5. A compound as in claim 2 wherein both R2 and R3 consist of p- and m-chlorine substituents.
6. A compound as in claim 1 wherein R3 is an adjacent ring forming a 2-naphthyl group.
7. A racemic mixture of the S,R and R,S enantiomers of a compound having the following structure:
wherein R1 is an alkane of 3 carbons or less, R2 and R3 independently consist of one or more substituents selected from the group consisting of hydrogen, halogen, alkane of 3 carbons or less, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate, adjacent ring forming a naphthyl group, and a combination thereof.
8. A racemic mixture as in claim 7 wherein R1 is a methyl group, and wherein, optionally, the amino nitrogen is present as a hydrochloric acid salt.
9. A racemic mixture as in claim 8 wherein either R2 or R3 consist of p- and m-chlorine substituents.
10. A racemic mixture as in claim 8 wherein both R2 and R3 consist of p- and m-chlorine substituents.
11. A racemic mixture as in claim 7 wherein R3 is an adjacent ring forming a 2-naphthyl group.
12. A method for alleviating one or more symptoms of a CNS disorder in an individual comprising administering to the individual a composition comprising a compound as in claim 1 in an amount effective to alleviate the symptoms of the CNS disorder, and wherein the administration of the composition alleviates one or more symptoms of the CNS disorder.